<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28178168</article-id>
      <article-id pub-id-type="pmc">5313025</article-id>
      <article-id pub-id-type="publisher-id">MD-D-16-06195</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000006087</article-id>
      <article-id pub-id-type="art-access-id">06087</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>5700</subject>
        </subj-group>
        <subj-group>
          <subject>Research Article</subject>
          <subject>Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation</article-title>
        <subtitle>Two Case Reports</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Koba</surname>
            <given-names>Taro</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kijima</surname>
            <given-names>Takashi</given-names>
          </name>
          <degrees>MD PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
          <xref rid="cor1" ref-type="corresp">
            <sup>&#x2217;</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takimoto</surname>
            <given-names>Takayuki</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hirata</surname>
            <given-names>Haruhiko</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Naito</surname>
            <given-names>Yujiro</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hamaguchi</surname>
            <given-names>Masanari</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Otsuka</surname>
            <given-names>Tomoyuki</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kuroyama</surname>
            <given-names>Muneyoshi</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nagatomo</surname>
            <given-names>Izumi</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takeda</surname>
            <given-names>Yoshito</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kida</surname>
            <given-names>Hiroshi</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kumanogoh</surname>
            <given-names>Atsushi</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Ling.</surname>
            <given-names>Shizhang</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine</aff>
      <aff id="aff2"><label>b</label>Department of Immunopathology, Immunology Frontier Research Center, Osaka University, Japan.</aff>
      <author-notes id="cor1">
        <corresp><label>&#x2217;</label>Correspondence: Takashi Kijima, Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka, Japan (e-mail: <email>tkijima@imed3.med.osaka-u.ac.jp</email>).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <volume>96</volume>
      <issue>6</issue>
      <elocation-id>e6087</elocation-id>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>10</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>16</day>
          <month>1</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>1</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2017 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-sa/4.0">
          <license-p>This is an open access article distributed under the Creative Commons Attribution-Share Alike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-sa/4.0">http://creativecommons.org/licenses/by-sa/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-96-e6087.pdf"/>
      <abstract>
        <title>Abstract</title>
        <sec>
          <title>Rationale:</title>
          <p>Most of nonsmall cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (<italic>EGFR</italic>) activating mutations eventually acquire resistance to the first EGFR-tyrosine kinase inhibitors (TKIs) therapy after varying periods of treatment. Of note, approximately one-third of those patients develop brain metastases, which deteriorate their quality of life and survival. The effect of systemic chemotherapy on brain metastases after acquisition of EGFR-TKI resistance is limited, and thus far, whole-brain radiation therapy, which may cause the harmful effect on neurocognitive functions, has been the only established therapeutic option for especially symptomatic brain metastases. Osimertinib is a third-generation oral, potent, and irreversible EGFR-TKI. It can bind to EGFRs with high affinity even when the <italic>EGFR</italic> T790M mutation exists in addition to the sensitizing mutations. Its clinical efficacy for NSCLC patients harboring the T790M mutation has already been shown; however, the evidence of osimertinib on brain metastases has not been documented well, especially in terms of the appropriate timing for treatment and its response evaluation.</p>
        </sec>
        <sec>
          <title>Patient concerns, Diagnoses, and Interventions:</title>
          <p>We experienced 2 NSCLC patients with the <italic>EGFR</italic> T790M mutation; a 67-year-old woman with symptomatic multiple brain metastases administered osimertinib as seventh-line chemotherapy, and a 76-year old man with an asymptomatic single brain metastasis administered osimertinib as fifth-line chemotherapy.</p>
        </sec>
        <sec>
          <title>Outcomes:</title>
          <p>These patients showed great response to osimertinib within 2 weeks without radiation therapy.</p>
        </sec>
        <sec>
          <title>Lessons:</title>
          <p>These are the first reports to reveal the rapid response of the brain metastases to osimertinib within 2 weeks. These cases suggest the possibility that preemptive administration of osimertinib may help patients to postpone or avoid radiation exposures. In addition, rapid reassessment of the effect of osimertinib on brain metastases could prevent patients from being too late to receive essential radiotherapy.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>brain metastasis</kwd>
        <kwd>osimertinib</kwd>
        <kwd>case report</kwd>
        <kwd>epidermal growth factor receptor</kwd>
        <kwd>nonsmall cell lung cancer</kwd>
        <kwd>T790M</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <label>1</label>
      <title>Introduction</title>
      <p>The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as the first-generation gefitinib and erlotinib and also the second-generation afatinib showed remarkable activity in nonsmall cell lung cancer (NSCLC) patients harboring <italic>EGFR</italic> activating mutations.<sup>[<xref rid="R1" ref-type="bibr">1</xref>&#x2013;<xref rid="R4" ref-type="bibr">4</xref>]</sup> However, most patients eventually acquire resistance to the first EGFR-TKI therapy after varying periods of treatment, and approximately one-third of patients develop brain metastases after acquisition of EGFR-TKI resistance.<sup>[<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>]</sup> Progressions of brain metastases are generally poor prognostic factors in patients with NSCLC,<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>]</sup> and the effect of systemic chemotherapy on brain metastases after acquisition of EGFR-TKI resistance is limited. Thus, whole-brain radiation therapy (WBRT), which may cause harmful effect on neurocognitive functions,<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> has been the only option for especially symptomatic multiple brain metastases.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup></p>
      <p>Osimertinib is the third-generation oral, potent, and irreversible EGFR-TKI. It can bind to EGFRs with high affinity even when the T790M mutation exists in addition to the EGFR-TKI-sensitizing mutations,<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> and clinical efficacy has already been shown.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> However, the effect of osimertinib on the central nervous system (CNS) metastases has not been documented well in clinical situations, except for a few preclinical studies.<sup>[<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref>]</sup> Furthermore, the time schedules for response evaluation are still controversial.</p>
      <p>We describe 2 patients who showed great response in symptomatic as well as asymptomatic brain metastases to osimertinib therapy within 2 weeks. Preemptive administration of osimertinib may help patients to postpone or avoid radiation exposures. In addition, rapid reassessment of the effect of osimertinib on brain metastases could prevent patients from being too late to receive essential radiotherapy.</p>
    </sec>
    <sec>
      <label>2</label>
      <title>Case reports</title>
      <p>Written informed consent was obtained from both patients for the publication of this manuscript and accompanying images.</p>
      <sec>
        <label>2.1</label>
        <title>Case 1</title>
        <p>A 67-year-old woman without a history of smoking, who had Beh&#xE7;et's disease, underwent right middle lobe resection of the lung because of an early stage of NSCLC 9 years ago. Multiple nodules emerged in both lungs on computed tomography (CT) images 7 years ago, which was recognized as a recurrence. An <italic>EGFR</italic> mutation analysis identified the <italic>EGFR</italic> L858R mutation in exon 21. Gefitinib was administered as first-line chemotherapy for 2 years and 11 months. After 3 lines of cytotoxic drug regimens (carboplatin plus pemetrexed, tegafur/gimeracil/oteracil plus bevacizumab, and docetaxel),erlotinib was administered as fifth-line chemotherapy and also as EGFR-TKI rechallenge, which failed in 3 and a half months. After 2 courses of vinorelbine administration as sixth-line chemotherapy, the patient complained of unbearable back pain, and spinal MRI examination detected multiple thoracolumbar bone metastases. Radiotherapy was conducted to control pain and prevent fractures. One month later, the patient complained of nausea and decrease of right grip strength. CT images revealed multiple contrast-enhanced nodules throughout the brain (Fig. <xref ref-type="fig" rid="F1">1</xref>A), and the symptoms were considered to be caused by brain metastases. After intravenous administration of corticosteroids and osmotic diuretics, the symptoms improved immediately. Bronchoscopy had been conducted as re-biopsy, detecting an additional mutation T790M in exon 20. As seventh-line chemotherapy, osimertinib (80&#x200A;mg/day) was administered from the next day the brain nodules were detected, when the grade of Eastern Cooperative Oncology Group (ECOG) performance status (PS) was 3. On day 5 after administration of osimertinib was started, a chest x-ray revealed shrinkage of a right pulmonary nodule (Fig. <xref ref-type="fig" rid="F2">2</xref>). Grade 3 stomatitis and grade 2 diarrhea, classified by Common Terminology Criteria for Adverse Events version 4.0, emerged on day 9 and day 10, respectively. Osimertinib administration was discontinued on day 11. CT images on day 13 revealed complete remission of brain metastases, except for 1 lesion in the left frontal lobe (Fig. <xref ref-type="fig" rid="F1">1</xref>B). Nausea and decrease of right grip strength have not recurred, despite discontinuation of corticosteroids and osmotic diuretics. Her ECOG PS gradually improved to 2. In addition, serum alkaline phosphatase was elevated in parallel with tumor shrinkage, probably reflecting the healing process of bone metastases converting from osteolytic to osteoblastic state which is known as the flare phenomenon.<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref>]</sup></p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Contrast-enhanced axial brain CT images of case 1. Multiple metastases at baseline. Complete remission of brain metastases except for 1 (white allow) in the left frontal lobe after 13 days osimertinib administration. CT&#x200A;=&#x200A;computed tomography.</p>
          </caption>
          <graphic xlink:href="medi-96-e6087-g001"/>
        </fig>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Chest x-rays of case 1. Shrinkage of the right pulmonary nodule after 5 days osimertinib administration.</p>
          </caption>
          <graphic xlink:href="medi-96-e6087-g002"/>
        </fig>
      </sec>
      <sec>
        <label>2.2</label>
        <title>Case 2</title>
        <p>A 76-year old man, with a 22.5 pack-year smoking history, underwent right upper lobe resection of the lung because of an early stage of NSCLC 10 years ago. An <italic>EGFR</italic> mutation analysis identified the <italic>EGFR</italic> exon 19 deletion. Multiple bone metastases as recurrence emerged 6 and a half years ago. Gefitinib was administered as first-line chemotherapy for 4 and a half years. Afatinib was administered for 10 months as EGFR-TKI rechallenge after sandwiching 4 courses of carboplatin plus pemetrexed with bevacizumab regimen between the EGFR-TKIs. While fourth-line chemotherapy tegafur/gimeracil/oteracil was being administered, pleural effusion with right-sided dominance was seen. A thoracentesis was conducted and detected the additional mutation T790M in exon 20. Osimertinib was administered as fifth-line chemotherapy, when the ECOG PS grade was 2. On day 10 after administration of osimertinib was started, brain CT images revealed the remission of single brain metastasis in the right parietal lobe, which was asymptomatic (Fig. <xref ref-type="fig" rid="F3">3</xref>). On day 14, decrease of pleural effusion and shrinkage of pulmonary nodules were recognized apparently on a chest x-ray (Fig. <xref ref-type="fig" rid="F4">4</xref>A). After a month, chest CT images revealed shrinkage of multiple lung metastases and decrease of left-sided pleural effusion (Fig. <xref ref-type="fig" rid="F4">4</xref> B). His ECOG PS gradually improved to 1, accompanied with the decrease of pleural effusion.</p>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Contrast-enhanced axial brain CT images of case 2. Complete remission of a single brain metastasis (white allow) in the right parietal lobe after 10 days osimertinib administration.</p>
          </caption>
          <graphic xlink:href="medi-96-e6087-g003"/>
        </fig>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Chest x-rays and axial chest CT images of case 2. Decrease of pleural effusion and shrinkage of pulmonary nodules on chest x-rays after 14 days osimertinib administration. Shrinkage of multiple lung metastases and decrease of left-sided pleural effusion on chest CT images after 31 days osimertinib administration.</p>
          </caption>
          <graphic xlink:href="medi-96-e6087-g004"/>
        </fig>
      </sec>
    </sec>
    <sec>
      <label>3</label>
      <title>Discussion</title>
      <p>We experienced 2 patients with NSCLC harboring the <italic>EGFR</italic> T790M mutation in addition to common activating mutations in whombrain metastases showed great response to the osimertinib treatment within 2 weeks. Although Ricciuti and coworkers reported 2 patients in whom brain metastases significantly responded to osimertinib treatment,<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> this is the first report ever to reveal the rapid response of the brain metastases to osimertinib within 2 weeks.</p>
      <p>Multiple brain metastases were symptomatic in the first case and WBRT was considered at first. However, disease progression was fast not only in the brain, but also in bones all over the body, and symptoms of the brain metastases were controllable by administration of corticosteroids and osmotic diuretics. We finally decided that the new systemic therapy with osimertinib should be given preference over the WBRT and succeeded in controlling brain metastases within 2 weeks.</p>
      <p>Evidence for chemotherapy including osimertinib on brain metastases after acquisition of resistance to prior EGFR-TKI therapy is insufficient. Although there are some reports of effectiveness by dose escalation of EGFR-TKIs,<sup>[<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>]</sup> pulsatile dosing of EGFR-TKIs<sup>[<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>]</sup>, and switch gefitinib to erlotinib.<sup>[<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref>]</sup> In the AURA phase II extension cohort (NCT01802632) and AURA2 phase II study (NCT02094261), total 162 of 411 patients (39%) had asymptomatic, stable brain metastases at entry.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> Objective response rate to osimertinib in patients with brain metastases was 56% (88/158; 95%CI 48, 64), comparable to 64% (154/239; 95%CI 58, 71) in patients without brain metastases.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> Thus, osimertinib may be effective enough in the treatment of NSCLC patients with brain metastases harboring the <italic>EGFR</italic> T790M mutation.</p>
      <p>Overcoming blood brain barrier (BBB) is the key to have enough drug efficacy for CNS metastases, although parenchymal brain metastases may cause BBB disruptions and increase drug penetration to the brain.<sup>[<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>]</sup> In a few preclinical models, osimertinib was suggested to have therapeutic potential in CNS metastases.<sup>[<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref>]</sup> Ballard and coworkers<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> reported that osimertinib showed a good Kp<sub>uu,brain</sub> value of 0.39 greater than other available EGFR-TKIs; Kp<sub>uu,brain</sub> is well established as a good predictor of BBB permeability, with values greater than 0.3 indicative of good diffusion across the BBB.<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup></p>
      <p>Compared to parenchymal brain metastases, leptomeningeal metastases appear to have distinct clinical courses and tumor biologies.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> Leptomeningeal metastases are especially life-threatening CNS complications, and EGFR-TKIs with high permeability to cerebrospinal fluid are essential. By update of ongoing phase I study for patients with leptomeningeal metastases from NSCLC called BLOOM (NCT02228369), osimertinib is expected to have enough efficacy by overcoming the BBB.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup></p>
      <p>WBRT has been the only option for symptomatic multiple brain metastases after acquisition of EGFR-TKI resistance.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> However, we should consider the potential harmful effect of radiotherapy, especially WBRT. Assessing impairment in neurocognitive function in patients treated with WBRT is difficult, because many variables including dysfunction caused by metastases themselves should be considered. Nonetheless, some studies supported these concerns with reasonable evidence,<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> and delaying radiotherapy in favor of osimertinib may be a valuable option.</p>
      <p>Although the dramatic responses to EGFR-TKIs are known to be observed in a few days in some cases, the time schedules for response evaluation are still controversial. Chang and coworkers<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> reported that a very high percentage (21/29; 72.4%) of patients who achieved partial response to EGFR-TKI therapy demonstrated an early radiological response in 2 weeks. In addition, we reported that evaluation using <sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> F-fluorodeoxyglucose uptake by positron emission tomography on day 2 after the initiation of gefitinib therapy is useful to predict the future clinical outcome of EGFR-TKI therapy at an early time point,<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> although positron emission tomography is not appropriate to assess brain metastases generally.</p>
      <p>Osimertinib is the only approved EGFR-TKI currently indicated for NSCLC patients harboring the <italic>EGFR</italic> T790M mutation. Patients acquire resistance to the osimertinib therapy after a median of 9.6 months of treatment.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> The <italic>EGFR</italic>C797S mutation has been reported as a major mechanism (6/15; 40%) of the resistance to osimertinib.<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> Not surprisingly, brain metastases that had developed during the first EGFR-TKI treatment might respond once to osimertinib therapy but would become resistant. It is unknown whether we should recommend a fourth-generation EGFR-TKI that can overcome the resistance mediated by C797Sor local radiotherapy.</p>
      <p>It is the best of all not to develop a brain metastasis in patients who are free of brain metastasis at diagnosis. There is no clinical evidence that supports osimertinib more efficacious in terms of postponing or preventing the development of brain metastases compared with first- and second-generation EGFR-TKIs. A phase III study FLAURA (NCT02296125) is ongoing comparing osimertinib with first-generation EGFR-TKIs as the first-line setting in patients with NSCLC harboring <italic>EGFR-</italic>activating mutations.<sup>[<xref rid="R34" ref-type="bibr">34</xref>]</sup> This study could reveal if osimertinib will postpone or prevent disease progression by brain metastases compared with first-generation EGFR-TKIs.</p>
      <p>In conclusion, osimertinib may be given priority over radiotherapy in terms of the therapeutic strategy for brain metastases of NSCLC harboring the <italic>EGFR</italic> T790M mutation, and the evaluation of treatment effect might be performed within 2 weeks. Further studies are needed to answer these clinical questions.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviations: BBB = blood brain barrier, CNS = central nervous system, ECOG = Eastern Cooperative Oncology Group, EGFR = epidermal growth factor receptor, NSCLC = non-small cell lung cancer, PS = performance status, TKI = tyrosine kinase inhibitors, WBRT = whole-brain radiation therapy.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p>The authors have no funding and conflicts of interest to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>[1]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namba</surname><given-names>Y</given-names></name><name><surname>Kijima</surname><given-names>T</given-names></name><name><surname>Yokota</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases</article-title>. <source>Clin Lung Cancer</source>
<year>2004</year>;<volume>6</volume>:<fpage>123</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15476598</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>[2]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porta</surname><given-names>R</given-names></name><name><surname>Sanchez-Torres</surname><given-names>JM</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Brain metastases from lung cancer responding to erlotinib: the importance of <italic>EGFR</italic> mutation</article-title>. <source>Eur Respir J</source>
<year>2011</year>;<volume>37</volume>:<fpage>624</fpage>&#x2013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">20595147</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>[3]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation</article-title>. <source>Lung Cancer</source>
<year>2012</year>;<volume>77</volume>:<fpage>556</fpage>&#x2013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">22677429</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>[4]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffknecht</surname><given-names>P</given-names></name><name><surname>Tufman</surname><given-names>A</given-names></name><name><surname>Wehler</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease</article-title>. <source>J Thorac Oncol</source>
<year>2015</year>;<volume>10</volume>:<fpage>156</fpage>&#x2013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">25247337</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>[5]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mujoomdar</surname><given-names>A</given-names></name><name><surname>Austin</surname><given-names>JH</given-names></name><name><surname>Malhotra</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases</article-title>. <source>Radiology</source>
<year>2007</year>;<volume>242</volume>:<fpage>882</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17229875</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>[6]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heon</surname><given-names>S</given-names></name><name><surname>Yeap</surname><given-names>BY</given-names></name><name><surname>Britt</surname><given-names>GJ</given-names></name><etal/></person-group>
<article-title>Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib</article-title>. <source>Clin Cancer Res</source>
<year>2010</year>;<volume>16</volume>:<fpage>5873</fpage>&#x2013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">21030498</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>[7]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langer</surname><given-names>J</given-names></name><name><surname>Mehta</surname><given-names>P</given-names></name></person-group>
<article-title>Current management of brain metastases, with a focus on systemic options</article-title>. <source>J ClinOncol</source>
<year>2005</year>;<volume>23</volume>:<fpage>6207</fpage>&#x2013;<lpage>19</lpage>.</mixed-citation>
      </ref>
      <ref id="R8">
        <label>[8]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamal-Hanjani</surname><given-names>M</given-names></name><name><surname>Spicer</surname><given-names>J</given-names></name></person-group>
<article-title>Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain</article-title>. <source>Clin Cancer Res</source>
<year>2012</year>;<volume>18</volume>:<fpage>938</fpage>&#x2013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">22167408</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>[9]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Bentzen</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Renschler</surname><given-names>M</given-names></name><name><surname>Mehta</surname><given-names>P</given-names></name></person-group>
<article-title>Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis</article-title>. <source>Int J Radiat Oncol Biol Phys</source>
<year>2008</year>;<volume>71</volume>:<fpage>64</fpage>&#x2013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">18406884</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>[10]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDuff</surname><given-names>G</given-names></name><name><surname>Taich</surname><given-names>J</given-names></name><name><surname>Lawson</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2013</year>;<volume>84</volume>:<fpage>1384</fpage>&#x2013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">23715918</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>[11]</label>
        <mixed-citation publication-type="book"><source>National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>&#xAE;</sup>), Non-Small Cell Lung Cancer Version 7.2015</source>, <comment><ext-link ext-link-type="uri" xlink:href="https://www.nccn.org/">https://www.nccn.org</ext-link></comment>.</mixed-citation>
      </ref>
      <ref id="R12">
        <label>[12]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>A</given-names></name><name><surname>Ashton</surname><given-names>E</given-names></name><name><surname>Ghiorghiu</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</article-title>. <source>Cancer Discov</source>
<year>2014</year>;<volume>4</volume>:<fpage>1046</fpage>&#x2013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">24893891</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>[13]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janne</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</article-title>. <source>N Engl J Med</source>
<year>2015</year>;<volume>372</volume>:<fpage>1689</fpage>&#x2013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">25923549</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>[14]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanjo</surname><given-names>S</given-names></name><name><surname>Ebi</surname><given-names>H</given-names></name><name><surname>Arai</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells</article-title>. <source>Oncotarget</source>
<year>2016</year>;<volume>7</volume>:<fpage>3847</fpage>&#x2013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">26716903</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>[15]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>P</given-names></name><name><surname>Yates</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity</article-title>. <source>Clin Cancer Res</source>
<year>2016</year>;<volume>22</volume>:<fpage>5130</fpage>&#x2013;<lpage>40</lpage>. <comment>Epub 2016</comment>.<pub-id pub-id-type="pmid">27435396</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>[16]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillespie</surname><given-names>J</given-names></name><name><surname>Alexander</surname><given-names>L</given-names></name><name><surname>Edelstyn</surname><given-names>A</given-names></name></person-group>
<article-title>Changes in 87mSr concentractions in skeletal metastases in patients responding to cyclical combination chemotherapy for advanced breast cancer</article-title>. <source>J Nucl Med</source>
<year>1975</year>;<volume>16</volume>:<fpage>191</fpage>&#x2013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">1113166</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>[17]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname><given-names>Y</given-names></name><name><surname>Kawamura</surname><given-names>K</given-names></name><name><surname>Ichikado</surname><given-names>K</given-names></name><name><surname>Yoshioka</surname><given-names>M</given-names></name></person-group>
<article-title>Alkaline phosphatase flare phenomenon following epidermal growth factor receptor-tyrosine kinase inhibitor treatment of non-small cell lung cancer: report of a case and case review</article-title>. <source>Respir Med Case Rep</source>
<year>2014</year>;<volume>13</volume>:<fpage>51</fpage>&#x2013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">26029561</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>[18]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricciuti</surname><given-names>B</given-names></name><name><surname>Chiari</surname><given-names>R</given-names></name><name><surname>Chiarini</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Osimertinib (AZD9291) and CNS response in two radiotherapy-naive patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer</article-title>. <source>Clin Drug Investig</source>
<year>2016</year>;<volume>36</volume>:<fpage>683</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation>
      </ref>
      <ref id="R19">
        <label>[19]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackman</surname><given-names>M</given-names></name><name><surname>Holmes</surname><given-names>J</given-names></name><name><surname>Lindeman</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib</article-title>. <source>J Clin Oncol</source>
<year>2006</year>;<volume>24</volume>:<fpage>4517</fpage>&#x2013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">16983123</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>[20]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Masago</surname><given-names>K</given-names></name><name><surname>Fukudo</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation</article-title>. <source>Cancer Chemother Pharmacol</source>
<year>2011</year>;<volume>68</volume>:<fpage>1089</fpage>&#x2013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">21681573</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>[21]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milton</surname><given-names>T</given-names></name><name><surname>Azzoli</surname><given-names>G</given-names></name><name><surname>Heelan</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer</article-title>. <source>Cancer</source>
<year>2006</year>;<volume>107</volume>:<fpage>1034</fpage>&#x2013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">16878326</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>[22]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grommes</surname><given-names>C</given-names></name><name><surname>Oxnard</surname><given-names>R</given-names></name><name><surname>Kris</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Pulsatile&#x2019; high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer</article-title>. <source>Neuro Oncol</source>
<year>2011</year>;<volume>13</volume>:<fpage>1364</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21865399</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>[23]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katayama</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>J</given-names></name><name><surname>Suda</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib</article-title>. <source>J Thorac Oncol</source>
<year>2009</year>;<volume>4</volume>:<fpage>1415</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19692934</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>[24]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Masago</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer</article-title>. <source>Cancer Chemother Pharmacol</source>
<year>2012</year>;<volume>70</volume>:<fpage>399</fpage>&#x2013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">22806307</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>[25]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>M</given-names></name><name><surname>Tsai</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies</article-title>. <source>Eur J Cancer</source>
<year>2015</year>;<volume>51</volume>:<fpage>S625</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation>
      </ref>
      <ref id="R26">
        <label>[26]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>J</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>The seed and soil hypothesis: vascularisation and brain metastases</article-title>. <source>Lancet Oncol</source>
<year>2002</year>;<volume>3</volume>:<fpage>53</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11905606</pub-id></mixed-citation>
      </ref>
      <ref id="R27">
        <label>[27]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>S</given-names></name><name><surname>Dziadziuszko</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name></person-group>
<article-title>Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases</article-title>. <source>Cancer Treat Rev</source>
<year>2014</year>;<volume>40</volume>:<fpage>716</fpage>&#x2013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">24759599</pub-id></mixed-citation>
      </ref>
      <ref id="R28">
        <label>[28]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadharajan</surname><given-names>S</given-names></name><name><surname>Winiwarter</surname><given-names>S</given-names></name><name><surname>Carlsson</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation</article-title>. <source>J Pharm Sci</source>
<year>2015</year>;<volume>104</volume>:<fpage>1197</fpage>&#x2013;<lpage>206</lpage>.<pub-id pub-id-type="pmid">25546343</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>[29]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hata</surname><given-names>A</given-names></name><name><surname>Katakami</surname><given-names>N</given-names></name><name><surname>Yoshioka</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases</article-title>. <source>Anticancer Res</source>
<year>2015</year>;<volume>35</volume>:<fpage>1025</fpage>&#x2013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">25667490</pub-id></mixed-citation>
      </ref>
      <ref id="R30">
        <label>[30]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study</article-title>. <source>J ClinOncol</source>
<year>2016</year>;<volume>3 4</volume>: <comment>abstr9002</comment>.</mixed-citation>
      </ref>
      <ref id="R31">
        <label>[31]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>Hsieh</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study</article-title>. <source>Biomed J</source>
<year>2015</year>;<volume>38</volume>:<fpage>221</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25179728</pub-id></mixed-citation>
      </ref>
      <ref id="R32">
        <label>[32]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>R</given-names></name><name><surname>Hirata</surname><given-names>H</given-names></name><name><surname>Tachibana</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung</article-title>. <source>Clin Cancer Res</source>
<year>2012</year>;<volume>18</volume>:<fpage>220</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22019513</pub-id></mixed-citation>
      </ref>
      <ref id="R33">
        <label>[33]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thress</surname><given-names>K</given-names></name><name><surname>Pawelets</surname><given-names>C</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M</article-title>. <source>Nat Med</source>
<year>2015</year>;<volume>21</volume>:<fpage>560</fpage>&#x2013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">25939061</pub-id></mixed-citation>
      </ref>
      <ref id="R34">
        <label>[34]</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suresh</surname><given-names>R</given-names></name><name><surname>Yuri</surname><given-names>R</given-names></name><name><surname>Karen</surname><given-names>T</given-names></name><name><surname>Jean-Charles</surname><given-names>S</given-names></name></person-group>
<article-title>A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-na&#xEF;ve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation</article-title>. <source>J ClinOncol</source>
<year>2015</year>;<volume>33</volume>: <comment>abstr TPS8102</comment>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
